Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Pan-Cancer Analysis of Tumor Mutations Points to Predictive Biomarkers

By LabMedica International staff writers
Posted on 05 Jul 2022

Quantifying the effectiveness of different cancer therapies in patients with specific tumor mutations is critical for improving patient outcomes and advancing precision medicine. More...

A key goal of precision medicine is to characterize how patients with specific genetic mutations respond to therapies.

Advances in modeling mutation–treatment interactions can potentially improve patient outcomes by recommending promising treatments based on each patient’s distinct tumor mutation profile. These interactions are especially important for guiding therapies for cancer, which is driven by heterogeneous mutations.

Biomedical Scientists at Stanford University (Stanford, CA, USA) and their colleagues used a gene-level analytical strategy, and searched for ties between tumor mutation profiles, cancer treatment histories, and survival patterns. Their dataset included electronic health record (EHR) entries and targeted Foundation Medicine panel sequence profiles for hundreds of cancer-related genes in more than 40,900 de-identified cancer patients who are part of the Flatiron Health-Foundation Medicine (New York, NY, USA) clinicogenomic database.

The participants included more than 12,900 individuals with advanced non-small cell lung cancer (NSCLC), nearly 7,900 metastatic breast cancer patients, almost 3,900 individuals with ovarian cancer, some 3,500 patients with metastatic pancreatic cancer, and thousands more patients with advanced bladder cancer, renal cell carcinoma, or melanoma. The team explained, noting that the results were verified using data for nearly 3,900 additional advanced lung, breast, or colorectal cancer cases from an American Association for Cancer Research (Philadelphia, PA, USA) dataset.

The team flagged 458 apparent mutation markers for survival in cancer patients receiving specific treatment protocols and uncovered specific mutations that typically co-occur with other tumor alterations. The investigators found that mutations in 42 genes tracked with survival outcomes in at least one of the cancer types considered, for example. These genes, in turn, showed almost 100 significant interactions.

Consistent with past studies that showed ties between EGFR inhibitor resistance and KRAS mutations in advanced NSCLCs, they saw shorter-than-usual survival for KRAS-mutated cases treated with EGFR inhibitors and enhanced survival in EGFR inhibitor-treated advanced NSCLC patients with KRAS-wild type tumors. When the team looked at mutation-mutation interactions across genes such as ALK, BRAF, EGFR, MET, RET, ROS1, ERBB2, or PIK3CA that are currently targeted by FDA-approved treatments, it found genes that were more or less likely to be mutated in conjunction with alterations affecting the targeted genes.

The authors concluded that their findings demonstrate that high-quality, real-world clinicogenomic data from patients with cancer can be an important resource for investigating such mutation-treatment interactions by capturing outcome information of patients on diverse treatments. As tumor sequencing data become increasingly linked to the EHR, such data combined with careful computational analysis can greatly benefit precision medicine. The study was published on June 30, 2022 in the journal Nature Medicine.

Related Links:
Stanford University 
Flatiron Health-Foundation Medicine 
American Association for Cancer Research 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.